Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
List view / Grid view
Filter the results
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
Development of cell line expression systems to produce biologic medicines is complex, multi-stage and time consuming, requiring specific expertise and access to suitable technologies. This can limit the development of novel medicines to existing users and may restrict companies developing new medicines. In this article, major methods and technologies used…
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Researchers have developed a way to produce proteins from lettuce which can effectively combat pulmonary arterial hypertension in animals.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
The interaction between proteins on apoptotic cells and receptors of the murine immune system prevents autoimmune reactions and could be the basis for new treatments, according to scientists.
Endogenous human antibodies can be used to build and dismantle 2D and 3D DNA nanostructures, finds new research.
Scientists have developed a new method that accelerates the design and engineering of potential medicines and vaccines using glycosylation.
A new process for identifying and biosynthesising drug candidates has been discovered by researchers at the Carl R Woese Institute for Genomic Biology.
A new method to reactivate 'tumour suppressor' genes switched off by cancer cells could lead to new targeted biotherapies for cancer.
Upstream bioprocessing is the epicentre of biologics development, wherein scientists piece together a series of carefully chosen processes with contributing components and parameters to enable the production of highly effective biotherapeutics. Unjulie Bhanot explains why an effective data management system is vital in this quest for the next big therapeutic.